Titan Medical Inc. Announces Addition of Dr. Dennis L. Fowler, MD, MPH as Development Consultant
TORONTO, ONTARIO -- (Marketwire) -- 06/07/12 -- Titan Medical Inc. (the "Company") (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that Dr. Dennis L. Fowler, MD, MPH has joined the Company as a consultant for the development of the Company's Insertable Robotic Effector Platform ("IREP") for single-site surgery.
"As a co-inventor of the IREP, Dr. Fowler's in-depth expertise in developing robotic surgical technologies and in performing laparoscopic surgery will be of great value to our team," said Craig Leon, Chief Executive Officer of Titan Medical Inc. "We believe, the advisory role he is going to take in the development of our single-site robotic surgery technology will be essential as we advance the IREP program from the development stage to clinical trials."
Dr. Fowler is Medical Director of the New York Presbyterian Hospital/Columbia Simulation Center and Director of the Reemtsma Center for Innovation and Outcomes Research in the Department of Surgery at Columbia. He joined the minimal access surgery field in 1990 when laparoscopic technology became available, and developed several new techniques for laparoscopic surgery, including laparoscopic colon surgery. In 2000, New York Presbyterian Hospital (NYPH) recruited him from his directorship of the Allegheny Center for Laparoscopic and Minimally Invasive Surgery in Pittsburgh to lead the newly formed Minimal Access Surgery Center (MASC) at both the Columbia and the Cornell campuses of NYPH. He continued in that role from 2000-2008 during which time he also served as Chief of the Division of General Surgery at Weill Cornell Medical College (2002-2004) and Vice President and Medical Director for Perioperative Services at NYPH/Columbia (2004-2008).
While Director of MASC, Dr. Fowler pioneered the field of minimal access surgery as an innovator of both devices and procedures. His work with MASC involved surgical skills training and assessment for Columbia University Department of Surgery residents as well as for licensed practitioners. He has published extensively on the topics of minimally invasive surgery, technology development, and surgical education. In 2008, he received his MPH degree from Columbia University, and now focuses on improving healthcare outcomes through health systems research; designing, testing, and commercializing innovative healthcare technology (e.g., surgical robotics to reduce the complexity of minimal access surgery); and designing, testing, and implementing simulation training for healthcare providers.
At the very beginning of his career, Dr. Fowler was a Surgical Endoscopy Fellow in 1979-80 at the Massachusetts General Hospital after having previously graduated from medical school and having completed a general surgery residency in Kansas City.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD)(OTCQX: TITXF) focused on the design, development and commercialization of new robotic surgical technologies. The Company is advancing the development of a robust product portfolio with the objective to meet current needs in surgical procedures which would benefit all stakeholders, including patients, surgeons, and hospitals. The Company's product portfolio includes solutions for both single-site and multi-port surgical procedures that are under-served by robotic and non-robotic minimally invasive techniques. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. According to a Robotic Surgery Equipment Manufacturing report, industry revenue is projected to increase at an average annual rate of 14.9% to $4.2 billion from 2011 to 2016. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 30, 2012 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext. 151) cleon@titanmedicalinc.com www.titanmedicalinc.com
Source: Titan Medical Inc.
Released June 7, 2012